Literature DB >> 10558975

In vivo efficacy of mefloquine for the treatment of Falciparum malaria in Brazil.

C Cerutti1, R R Durlacher, F E de Alencar, A A Segurado, L W Pang.   

Abstract

Ninety-four patients with falciparum malaria were treated with mefloquine (1000-mg single dose) and remained hospitalized in a malaria-free area for a minimum of 28 days. There was 1 parasitologic failure (grade I resistance [RI]) for a 99% cure rate (95% confidence interval, 94.2%-99.7%). Mean parasite clearance time by thick smear was 45.7 h (SD, 11.4 h). The subject in whom therapy failed had a parasite clearance time (71 h) >2 SD above the population mean. His plasma mefloquine level 48 h after administration was lower (578 ng/mL) than the range of levels from 8 randomly selected cured subjects (834-2360 ng/mL). The IC50 to mefloquine for the recrudescent strain of the RI failure was in the upper 90th percentile of IC50 values from 30 cured subjects. These results show a high mefloquine cure rate but document the onset and mechanism of the emergence of resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10558975     DOI: 10.1086/315141

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Differential recognition of Plasmodium falciparum merozoite surface protein 2 variants by antibodies from malaria patients in Brazil.

Authors:  Kelly A Kanunfre; Fabiana M S Leoratti; Erika H E Hoffmann; Rui R Durlacher; Antônio W Ferreira; Sandra L Moraes-Avila; Marcelo U Ferreira
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Recent Advances in the Prophylaxis and Treatment of Malaria.

Authors:  Annie-Claude Labbé; Mona R. Loutfy; Kevin C. Kain
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

Review 3.  Recent advances in malaria drug discovery.

Authors:  Marco A Biamonte; Jutta Wanner; Karine G Le Roch
Journal:  Bioorg Med Chem Lett       Date:  2013-03-27       Impact factor: 2.823

Review 4.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  No Clinical or Molecular Evidence of Plasmodium falciparum Resistance to Artesunate-Mefloquine in Northwestern Brazil.

Authors:  Simone Ladeia-Andrade; Gladson Naber P de Melo; Rita de Cássia de Souza-Lima; Laís C Salla; Melissa S Bastos; Priscila T Rodrigues; Francisco das Chagas O Luz; Marcelo U Ferreira
Journal:  Am J Trop Med Hyg       Date:  2016-04-11       Impact factor: 2.345

Review 6.  Combination therapy for malaria: the way forward?

Authors:  François Nosten; Philippe Brasseur
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Regulation of extracellular ATP in human erythrocytes infected with Plasmodium falciparum.

Authors:  Cora Lilia Alvarez; Julieta Schachter; Ana Acacia de Sá Pinheiro; Leandro de Souza Silva; Sandra Viviana Verstraeten; Pedro Muanis Persechini; Pablo Julio Schwarzbaum
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

8.  Analysis of polymorphisms in Plasmodium falciparum genes related to drug resistance: a survey over four decades under different treatment policies in Brazil.

Authors:  Juliana Inoue; Dinora Lopes; Virgílio do Rosário; Marta Machado; Angélica D Hristov; Giselle Fmc Lima; Maria J Costa-Nascimento; Aluísio C Segurado; Silvia M Di Santi
Journal:  Malar J       Date:  2014-09-19       Impact factor: 2.979

9.  Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.

Authors:  Julie Gutman; Michael Green; Salomon Durand; Ofelia Villalva Rojas; Babita Ganguly; Wilmer Marquiño Quezada; Gregory C Utz; Laurence Slutsker; Trenton K Ruebush; David J Bacon
Journal:  Malar J       Date:  2009-04-09       Impact factor: 2.979

10.  Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model.

Authors:  Catherine Mullié; Nicolas Taudon; Camille Degrouas; Alexia Jonet; Aurélie Pascual; Patrice Agnamey; Pascal Sonnet
Journal:  Malar J       Date:  2014-10-16       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.